Search

Displaying results 2471 - 2480 of 8974 in total
  1. Drug

    Sparteine

    go.drugbank.com/drugs/DB06727
    ApprovedWithdrawn

    Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents.

  2. Drug

    Equine Botulinum Neurotoxin B Immune FAB2

    go.drugbank.com/drugs/DB13903
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients.

  3. Drug

    Sulfadoxine

    go.drugbank.com/drugs/DB01299
    ApprovedInvestigationalWithdrawn

    A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.

  4. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    Firdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 [L4819]. … Amifampridine phosphate is a more stable salt that serves as an active ingredient of EMA-approved Firdapse, which was previously marketed as Zenas.

  5. Drug

    Sulconazole

    go.drugbank.com/drugs/DB06820
    Approved

    [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial fungal infections.[A255612] … Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  6. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … due to non-selective steroidal activities [A275513, A275514].

  7. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    [A232905,L32539] For example, bethanechol is readily used to treat postoperative or postpartum urinary retention. … An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]

  8. Drug

    Flutamide

    go.drugbank.com/drugs/DB00499
    ApprovedInvestigational

    An antiandrogen with about the same potency as cyproterone in rodent and canine species.

  9. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]

  10. Drug

    Ioversol

    go.drugbank.com/drugs/DB09134
    ApprovedInvestigational

    [L41780] Ioversol is a highly hydrophilic agent considered to be generally safe[L41790]; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol … [L41780] Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left

    Categories: Compounds used in a research, industrial, or household setting